Investment Summary |
|
|---|---|
| Date | 2015-02-17 |
| Target | Altimmune |
| Sector | Life Science |
| Investor(s) | Truffle Capital |
| Deal Type | Stake Purchase |
SEARCH BY
| Category | Private Equity Firm |
|---|---|
| Founded | 2001 |
| PE ASSETS | 700M EUR |
| Size | Middle-Market |
| Type | Sector Focused |
Truffle Capital is a French private equity firm focused on majority investments in life science and information technology companies. Within IT, Truffle seeks businesses dealing in mobile content and connectivity, internet, technical software, IT security, and VOIP. Within the life science sector, the Firm looks at opportunities in therapeutic drugs and vaccines, medical devices, as well as other breakthrough technologies. Truffle Capital was formed in 2001 and is based in Paris.
| DEAL STATS | # |
|---|---|
| Overall | 41 of 45 |
| Sector: Life Science M&A | 8 of 9 |
| Type: Stake Purchase M&A Deals | 3 of 4 |
| State: Maryland M&A | 1 of 1 |
| Country: United States M&A | 3 of 3 |
| Year: 2015 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-02-17 |
Immune Targeting Systems
London, United Kingdom Immune Targeting Systems Ltd. develops synthetic vaccines for mutating viruses. Immune Targeting Systems enabling the T-cell vaccine platform enables it to target highly conserved parts of the virus (“antigens”) and direct a T-cell immune response to those cells in the body infected with one of these difficult viruses. Immune Targeting Systems was founded in 2003 and is based in London, United Kingdom. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-06-23 |
Abivax
Paris, France Abivax is a clinical-stage company leveraging its antiviral and immune platforms to optimize its drug candidates to cure HIV and treat inflammatory conditions, as well as cancer. Abivax was founded in 2013 and is based in Paris, France. |
Sell | - |
